搜索
Edwards Lifesciences Corp
EW添加自选
86.226USD
+0.346+0.40%
交易中 （美东）报价延迟15分钟
49.75B总市值
45.79市盈率 TTM
关键数据
86.190今开
87.200最高
2.01M成交量
45.79市盈率 TTM
25.79市盈率动
--股息TTM
0.35%换手率
85.880昨收
85.460最低
123.11M成交额
11.92市盈率静
4.82市净率
0.00%股息率 TTM
8.15%ROA
88.28052周最高
0.45量比
4.17B净利润
577.00M总股本
1.8830每股收益TTM
0.87Beta
10.52%ROE
72.30052周最低
2.03%振幅
78.01%毛利率
49.75B总市值
2.29回报/风险
1.41%风险率
TradingKey Edwards Lifesciences Corp股票评分
单位: USD 更新时间: 2026-06-22操作建议
Edwards Lifesciences Corp当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在医疗设备与耗材行业排名17/203位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价96.03。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Edwards Lifesciences Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
19°C
过冷
过热
看好
Edwards Lifesciences Corp亮点
亮点风险
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
业绩高增长
公司营业收入稳步增长，连续3年增长21.11%
估值高估
公司最新PE估值45.61，处于3年历史高位
机构减仓
最新机构持股539.60M股，环比减少2.34%
安德烈亚斯·霍尔沃森持仓
明星投资者安德烈亚斯·霍尔沃森持仓，最新持仓市值1.02M
分析师目标
根据
34
位分析师
买入
评级
96.026
目标均价
+9.92%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Edwards Lifesciences Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Edwards Lifesciences Corp简介
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
公司代码EW
公司Edwards Lifesciences Corp
CEOZovighian (Bernard J)
网址https://www.edwards.com
相关品种
热门品种
常见问题
Edwards Lifesciences Corp(EW)的当前股价是多少？
Edwards Lifesciences Corp(EW)的当前股价是 85.88。
Edwards Lifesciences Corp的股票代码是什么？
Edwards Lifesciences Corp的股票代码是EW。
Edwards Lifesciences Corp股票的52周最高点是多少？
Edwards Lifesciences Corp股票的52周最高点是88.28。
Edwards Lifesciences Corp股票的52周最低点是多少？
Edwards Lifesciences Corp股票的52周最低点是72.30。
Edwards Lifesciences Corp的市值是多少？
Edwards Lifesciences Corp的市值是49.45B。
现在Edwards Lifesciences Corp(EW)的股票是买入、持有还是卖出？
根据分析师评级，Edwards Lifesciences Corp(EW)的总体评级为买入，目标价格为96.03。
Edwards Lifesciences Corp(EW)股票的每股收益（EPS TTM）是多少
Edwards Lifesciences Corp(EW)股票的每股收益（EPS TTM）是1.84。
